FCX-007- Emerging Drug Insight and Market Forecast - 2030
発行: DelveInsight Business Research LLP
ページ情報: 英文 50 Pages
FCX-007は Fibrocell の臨床段階にあり、タンパク質COL7の欠乏によって引き起こされる先天性および進行性の孤児の皮膚疾患であるRDEBの治療のための遺伝子治療製品候補です。
当レポートでは、米国、欧州5ヶ国（ドイツ、フランス、イタリア、スペイン、英国）、および日本の7つの主要市場における FCX-007 について詳細に説明し (作用機序、投与量、合成経路、規制のマイルストーンを含む研究開発活動、およびその他の開発活動)、SWOT分析、市場の競合企業、およびその他の新たな治療法を含む将来の市場評価を提供しています。
"FCX-007- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Epidermolysis bullosa in 7 Major Markets. A detailed picture of the FCX-007 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
FCX-007 is Fibrocell's clinical stage, gene therapy product candidate for the treatment of RDEB, a congenital and progressive orphan skin disease caused by the deficiency of the protein COL7. FCX-007 is a genetically-modified autologous fibroblast that encodes the gene for COL7. By genetically modifying autologous fibroblasts ex vivo to produce COL7, culturing them and then treating wounds locally via injection, FCX-007 offers the potential to address the underlying cause of the disease by providing high levels of COL7 directly to the affected areas while avoiding systemic distribution. Fibrocell is developing FCX-007 in collaboration with Intrexon. In addition, Fibrocell is working in collaboration with Castle Creek Pharmaceuticals to develop and commercialize FCX-007 for the treatment of RDEB. Castle Creek is recognized for its innovation in drug development for rare skin diseases and its commitment to bringing novel therapies to those living with epidermolysis bullosa.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of FCX-007 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
The report provides the clinical trials information of FCX-007 covering trial interventions, trial conditions, trial status, start and completion dates.